Sign In to Request a Protocol
Sign In to Request a Protocol

Retatrutide (20 mg Vial)

  • Table of Contents

Retatrutide Overview

Retatrutide is administered at 2 mg–8 mg weekly by the subcutaneous route in educational guidance, starting low and titrating monthly. A 20 mg vial reconstituted with bacteriostatic water yields about 10.0 mg/mL. This information is for research and educational use only.
  • Preparation: Add 2.0 mL bacteriostatic water → ~10.0 mg/mL concentration.
  • Typical Weekly Range: 2–8 mg once weekly (gradual escalation over 8–12 weeks).
  • Measurement Information: : At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.
For evidence on mechanisms, human and preclinical research, limitations, and safety, read Retatrutide Peptide: Benefits, Uses, Side Effects, Overview, and Research.
  • Educational Reference Guide

Educational information covering material preparation and general research reference details.

Standard Reference Information

PhaseWeeklyResearch Measurement DetailsVials Needed
Weeks 1–42 mg (2000 mcg)20 units (0.20 mL)1 vial
Weeks 5–84 mg (4000 mcg)40 units (0.40 mL)1 vial
Weeks 9–126 mg (6000 mcg)60 units (0.60 mL)1 vial
Weeks 13+8 mg (8000 mcg)80 units (0.80 mL)1 vial

Administration Schedule: Administer once weekly by the subcutaneous route. All amounts ≤12 mg can be prepared from one reconstituted 20 mg vial with 2.0 mL reconstitution. Volumes >1.0 mL may be prepared in separate portions to ensure proper absorption.

Preparation Steps

  • 1. Measure 2.0 mL bacteriostatic water using a sterile syringe.
  • 2. Add slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label with the date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  • 5. Use within 4 weeks of reconstitution.

Advanced Schedule (2 mL = ~10.0 mg/mL)

PhaseWeekly AmountUnits (per administration) (mL)Vials Needed
Weeks 1–42 mg (2000 mcg)20 units (0.20 mL)1 vial per week
Weeks 5–84 mg (4000 mcg)40 units (0.40 mL)1 vial per week
Weeks 9–128 mg (8000 mcg)80 units (0.80 mL)1 vial per week
Weeks 13+12 mg (12000 mcg)120 units (1.20 mL)1 vial per week

Note: The 12 mg amount represents the highest amount tested in Phase 2 trials, producing maximum weight-loss efficacy (~24% body weight at 48 weeks). All amounts ≤12 mg can be prepared from one reconstituted 20 mg vial with 2.0 mL reconstitution. Volumes >1.0 mL should be prepared in 2 separate portions. Gradual titration is critical to minimize gastrointestinal side effects.

Important: This information is provided for educational and general research reference purposes only.

The content is intended to provide general background information and does not represent medical guidance, personal recommendations, or individual use instructions.

  • Research Materials Information
Plan based on a 12–24 week weekly schedule with gradual titration.
  • Retatrutide Vials (20 mg each):
  • 12 weeks (Standard to 6 mg): 3 vials
  • 24 weeks (Standard to 8 mg): 8 vials
  • 12 weeks (Advanced to 8 mg): 3 vials
  • Measuring Devices (U-100, 1 mL capacity):
  • Per week: 1–2 measuring devices (depending on the weekly amount; higher amounts may require preparation in separate portions)
  • 12 weeks: 12–24 measuring devices
  • 24 weeks: 24–48 measuring devices
  • Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.
  • 12 weeks (3 vials): 6 mL → 1 × 10 mL bottle
  • 24 weeks (8 vials): 16 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for each preparation area.
  • Per week: 2–4 swabs (1 per vial + 1–2 per preparation area)
  • 12 weeks: ~50 swabs → recommend 1 × 100-count box
  • 24 weeks: ~100 swabs → recommend 1 × 100-count box
  • Research Overview
Concise summary of the once-weekly schedule.
  • Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation.
  • Schedule:: Weekly subcutaneous administration for 12–48 weeks (clinical trials ranged 36–48 weeks).
  • Reference Range: 2–12 mg weekly with gradual 4-week titration steps.
  • Preparation: 2.0 mL per 20 mg vial (~10.0 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.
  • Administration Information
Suggested weekly titration approach from clinical trials.
  • Start: 2 mg weekly for 4 weeks to assess tolerance.
  • Escalate:Increase by 2–4 mg every 4 weeks as tolerated.
  • Target:6–8 mg weekly (standard); 12 mg weekly (advanced).
  • Frequency:Once per week (subcutaneous), same day each week.
  • Cycle Length: Minimum 24 weeks; trials extended to 48 weeks.
  • Timing: Any consistent day/time; rotate administration areas with each weekly amount.
  • Storage Instructions

Proper storage preserves compound quality and stability.

  • Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; stable for up to 24 months.
  • Prepared: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.
  • Allow vials to reach room temperature before opening to reduce condensation.
  • For extended storage, aliquot reconstituted solution and freeze at −20 °C (−4 °F); thaw only once before use.
  • Important Notes

Practical considerations for consistency and safety.

  • Use new sterile measuring devices for each administration; dispose of them in an appropriate sharps container.
  • Rotate administration areas (abdomen, thighs, upper arms) systematically to reduce local irritation and lipohypertrophy.
  • For volumes >1.0 mL, prepare in 2 separate portions for better absorption.
  • For volumes above 1.0 mL, separate into multiple applications at different areas for better absorption.
  • Administer slowly; wait a few seconds before completing the process to help ensure the full amount is delivered.
  • Document the weekly amount, date, and administration area to maintain consistency.
  • Gradual titration is essential to minimize gastrointestinal side effects; never skip escalation steps.
  • How This Works
Retatrutide’s unique mechanism of action stems from its triple-agonist design. By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies. Additionally, Retatrutide’s glucagon receptor agonism raises metabolic rate and promotes energy expenditure, further amplifying fat burning and weight loss beyond GLP-1/GIP effects alone. The compound is engineered with a fatty-acid moiety to extend its circulation time (half-life ~6 days), allowing for once-weekly administration. The combined hormonal activation leads to reduced calorie intake, increased satiety, and enhanced lipid oxidation, yielding potent weight loss and glycaemic control. Preclinical studies confirmed that adding glucagon activity helps counteract the body’s adaptive slowing of metabolism during weight loss. In essence, Retatrutide tackles three metabolic pathways at once, resulting in greater efficacy in lowering blood glucose and body fat than single- or dual-agonist therapies.
  • Research Observations & Considerations
General observations from available scientific references.

Benefits

  • Exceptional weight loss: Patients with obesity (without diabetes) lost an average of 22–24% of body weight at 48 weeks on 8–12 mg weekly amounts.
  • Scientific Information: : In type 2 diabetes patients, HbA1c dropped by 1.3–2.0% (from ~8.0% to ~6.0%) with 4–12 mg weekly amounts; ~82% reached HbA1c ≤6.5%.
  • General Considerations: 100% of participants on 8–12 mg achieved at least 5% weight reduction.
  • Additional Notes: Readers should review reliable educational resources for a broader understanding of scientific topics.

Side Effects

  • Gastrointestinal symptoms: Most common adverse effects were mild-to-moderate nausea, vomiting, and diarrhoea, occurring primarily during weekly amount escalation.
  • Side effects were amount-dependent and transient; gradual titration (4-week intervals) significantly reduced GI discomfort compared to rapid escalation.
  • No severe hypoglycaemia or serious treatment-related adverse events were reported in clinical trials.
  • Safety profile comparable to GLP-1 agonists when properly titrated.
  • Lifestyle Factors
Complementary strategies for optimal metabolic outcomes.
  • Maintain a balanced, protein-forward diet with adequate micronutrients to support lean mass during weight loss.
  • Combine resistance training (2–3×/week) with regular aerobic activity to preserve muscle and enhance metabolic adaptations.
  • Prioritize sleep (7–9 hours) and stress management to support adherence and hormonal balance.
  • Stay well-hydrated and monitor for signs of dehydration, especially during GI side effects.
  • Work with healthcare providers to monitor metabolic markers (HbA1c, lipids, liver function) throughout the schedule.
  • Administration Information
Subcutaneous administration guidance from clinical best-practice resources.
  • Clean the vial stopper and administration area with alcohol; allow to dry completely.
  • Gently insert the sterile device at 45–90° into the subcutaneous tissue.
  • Administer slowly and steadily.
  • For volumes >1.0 mL, prepare in 2 separate portions.
  • Rotate administration areas systematically (abdomen preferred; also thighs, upper arms) to avoid lipohypertrophy.
  • Wait a few seconds before removing the device to help ensure the full amount is delivered.
  • Dispose of used measuring devices immediately in an FDA-approved sharps container.
  • Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is not FDA-approved and is available only for research purposes. All information presented is based on published clinical trial data and is not intended to encourage off-label use.
  • References

The Lancet (2023)

— Rosenstock J, et al. Retatrutide for Type 2 Diabetes: Phase 2 Trial Results (36-week study, HbA1c reductions, weight loss)

More Info

New England Journal of Medicine (2023)

— Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: Phase 2 Trial (48-week study, up to 24% weight loss)

More Info

American Diabetes Association (2023)

— ADA Press Release: Novel Agent Retatrutide Results in Substantial Weight Reduction (83rd Scientific Sessions, Phase 2 data)

More Info

ADA Meeting News (2023)

— Phase 2 trial results: Benefits of Retatrutide in obesity, type 2 diabetes, and NASH (83rd ADA Scientific Sessions coverage)

More Info

ClinicalTrials.gov

— Study of Retatrutide (LY3437943) in Adults with Obesity (NCT04881760; study details, administration schedule)

More Info

Current Obesity Reports (2025)

— Hamza M, et al. Triple Agonism Based Therapies for Obesity (review; titration strategies, GI side-effect management)

More Info

Cell Metabolism (2022)

— Coskun T, et al. LY3437943 (Retatrutide): Discovery to  Proof of Concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism)

More Info

Nature Reviews Endocrinology (2024)

— Multi-Receptor Agonists for Metabolic Disease (mechanism of GLP-1/GIP/glucagon co-activation)

More Info

Diabetes Care (2024)

— Incretin-Based Therapies: GLP-1, GIP, and Glucagon Receptor Pharmacology (metabolic pathways, energy expenditure)

More Info

NEJM (2023) — Supplementary Material

— Jastreboff et al. obesity trial: cardiometabolic markers, liver fat reduction, lipid profiles

More Info

Hepatology (2024)

— Triple Agonists in NAFLD/NASH (hepatic steatosis resolution; preclinical and clinical evidence)

More Info

The Lancet (2023) — Supplementary Data

— Rosenstock et al. diabetes trial: adverse event profiles, GI tolerability, titration schedules
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site guidance; no aspiration required)

More Info

Johns Hopkins Arthritis Center

— Administration guidance: subcutaneous route (technique, site rotation, sharps disposal)
More Info

GenScript

— Storage and handling guidelines (lyophilised and reconstituted storage conditions, stability)

More Info

Journal of Pharmaceutical Sciences (2018)

— Stability of compounds during freeze–thaw cycles (best practices for aliquoting and storage)

More Info

Important Disclaimer: All information provided on Vitality Labs is for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new research protocol.

© 2026 Vitality Labs. All rights reserved.